Monday, April 21, 2025 7:48:34 AM
You can't refute the scientific facts
Instead of addressing it with a reasoned response, you've defaulted to a simplistic reply lacking any supporting evidence.
You're out of your depth and it shows. Come back when you're ready to discuss it like an adult.
IsoPet (aka Radiogel) is typically administered in the range of about 200 Gy up to a maximum of 400Gy. I'll give you the benefit of doubt and go with a 500 Gy safety test.
IsoPet (aka Radiogel) is available at activities ranging from less than <1 mCi to about 30 mCi (approximately 37 to 1110 MBq).
Safety Test - 30-gram tumor(a typical mass for thyroid cancer
Manufactured Activity: A single vial at 30 mCi (30,000µCi)
Dosimetry Conversion: ~54? Ci of Y-90 delivers 100 Gy to 1g, i.e. about 1.85 Gy per µCi per gram
Instead of addressing it with a reasoned response, you've defaulted to a simplistic reply lacking any supporting evidence.
You're out of your depth and it shows. Come back when you're ready to discuss it like an adult.
IsoPet (aka Radiogel) is typically administered in the range of about 200 Gy up to a maximum of 400Gy. I'll give you the benefit of doubt and go with a 500 Gy safety test.
IsoPet (aka Radiogel) is available at activities ranging from less than <1 mCi to about 30 mCi (approximately 37 to 1110 MBq).
Safety Test - 30-gram tumor(a typical mass for thyroid cancer
Manufactured Activity: A single vial at 30 mCi (30,000µCi)
Dosimetry Conversion: ~54? Ci of Y-90 delivers 100 Gy to 1g, i.e. about 1.85 Gy per µCi per gram
Recent RDGL News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2026 08:45:22 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:44:48 PM
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 03/06/2026 05:15:04 AM
- Form 1-A/A - Offering Statement [Regulation A]: [Amend] • Edgar (US Regulatory) • 03/04/2026 04:48:52 PM
- Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites • GlobeNewswire Inc. • 02/17/2026 01:30:00 PM
- Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™ • GlobeNewswire Inc. • 02/10/2026 01:30:00 PM
- Vivos Inc Updates Human Therapy Progress in India • GlobeNewswire Inc. • 02/03/2026 01:30:00 PM
- Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL™ Trademark Approvals • GlobeNewswire Inc. • 01/28/2026 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2026 04:06:21 PM
- Vivos Inc Summarizes Progress in its Animal Therapy Division • GlobeNewswire Inc. • 12/22/2025 05:56:08 PM
- Vivos Inc Summarzes Preogress in its Animal Therapy Division • GlobeNewswire Inc. • 12/22/2025 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/09/2025 09:00:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2025 12:34:42 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 11:08:03 AM
- Vivos Inc. Issues Shareholder Update Letter • GlobeNewswire Inc. • 11/06/2025 01:30:00 PM
- Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics • GlobeNewswire Inc. • 10/29/2025 12:30:00 PM
- Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., to Support IDE Submission for RadioGel® • GlobeNewswire Inc. • 10/27/2025 12:30:00 PM
- Vivos Inc Board Authorizes Vivos Inc to Establish a Corporate Entity in India • GlobeNewswire Inc. • 09/29/2025 05:46:00 PM
- Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India • GlobeNewswire Inc. • 09/29/2025 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2025 08:01:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2025 07:32:46 PM
